CN105246474B - Extension service life composition containing (+) syringaresinol - Google Patents
Extension service life composition containing (+) syringaresinol Download PDFInfo
- Publication number
- CN105246474B CN105246474B CN201480031690.5A CN201480031690A CN105246474B CN 105246474 B CN105246474 B CN 105246474B CN 201480031690 A CN201480031690 A CN 201480031690A CN 105246474 B CN105246474 B CN 105246474B
- Authority
- CN
- China
- Prior art keywords
- syringaresinol
- service life
- constituent
- acid
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KOWMJRJXZMEZLD-HCIHMXRSSA-N (+)-syringaresinol Chemical compound COC1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-HCIHMXRSSA-N 0.000 title claims abstract description 76
- WMBGFAAYQOSHMX-UHFFFAOYSA-N (+)-syringaresinol Natural products COc1cc(cc(OC)c1O)C2OCC3(C)C(OCC23C)c4cc(OC)c(O)c(OC)c4 WMBGFAAYQOSHMX-UHFFFAOYSA-N 0.000 title claims abstract description 37
- SGPJPUBLNFSWLJ-UHFFFAOYSA-N eudesmin A Natural products COc1cc(OC)cc(c1)C2OCC3C2COC3c4cc(OC)cc(OC)c4 SGPJPUBLNFSWLJ-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title description 10
- 239000000470 constituent Substances 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 abstract description 14
- 239000004480 active ingredient Substances 0.000 abstract description 11
- 241000244203 Caenorhabditis elegans Species 0.000 abstract description 8
- 230000002068 genetic effect Effects 0.000 abstract description 4
- 230000032683 aging Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- -1 phenyl Chemical group 0.000 description 6
- 241000244206 Nematoda Species 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- PZQICMZUJZVGNC-FNAHDJPLSA-N (-)-syringaresinol Natural products COc1cc(cc(OC)c1O)[C@@H]1OC[C@@]2(O)[C@@H](OC[C@@]12O)c1cc(OC)c(O)c(OC)c1 PZQICMZUJZVGNC-FNAHDJPLSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- MLMQPDHYNJCQAO-UHFFFAOYSA-N 3,3-dimethylbutyric acid Chemical compound CC(C)(C)CC(O)=O MLMQPDHYNJCQAO-UHFFFAOYSA-N 0.000 description 1
- OJDZHBWEGLIKRW-UHFFFAOYSA-N 3-[(4-hydroxyphenyl)methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(CC=2C=CC(O)=CC=2)=C1 OJDZHBWEGLIKRW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000244202 Caenorhabditis Species 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001167795 Escherichia coli OP50 Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical class OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000007166 healthy aging Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940066779 peptones Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- KOWMJRJXZMEZLD-UHFFFAOYSA-N syringaresinol Chemical compound COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-UHFFFAOYSA-N 0.000 description 1
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of extension service life constituent, more particularly to a kind of extension service life constituent for containing (+) syringaresinol.The constituent of the present invention can extend the service life of individual whereby using (+) syringaresinol contained as active ingredient.It is used as the constituent of the present invention of active ingredient by (+) syringaresinol that will contain, can extend has the drosophila of perfect homology and the service life of Caenorhabditis elegans in genetic aspect and people, and when using it for mammal mouse, the number of the index, i.e. CD4, CD8 memory cell of the known predictable volume lifetime of industry can be reduced.
Description
【Technical field】
The present invention relates to a kind of extension service life composition, more particularly to a kind of extension for containing (+) syringaresinol
Service life constituent.
【Background technology】
It has been generally acknowledged that ageing process is typically subject to the influence of the factors such as heredity, environment and living habit, also someone recognizes
Not exceed 30% or so in the ratio that entire ageing process occupies by qualitatively aging factor, that is, gene.It therefore can
To think that the process of aging can be adjusted by adjusting posteriority aging factor, such as prevent aging or delaying aging, these
It can be relevant with the method for extending the service life.The life-time dilatation as Disease iatrotechnics proves is related with the reduction of disease
Connection, it can be considered that can be realized by the above method healthy, in high spirits, more to the contribution of society and without burden
Successful aging or successful aging (healthy aging).
【Invention content】
The purpose of the present invention is to provide a kind of compositions for extending individual life span.
The present invention provides (+) syringaresinol that will contain and is used as the extension service life of active ingredient to achieve the above object
Constituent.
The constituent of the present invention contains (+) syringaresinol as active ingredient, can extend the service life of individual whereby.It is logical
It crosses constituent of (+) syringaresinol as the present invention of active ingredient, can extend has height phase in genetic aspect and people
The drosophila of the same sex and the service life of Caenorhabditis elegans, when using it for mammal mouse, it is possible to reduce industry is known
As prediction individual life span index CD4, CD8 memory cell number.
【Description of the drawings】
Fig. 1 is to represent to take in the life curve figure of the drosophila of (+) syringaresinol；
Fig. 2 is the mortalogram for representing to take in the drosophila of (+) syringaresinol；
Fig. 3 is to represent to take in the life curve figure of the nematode of (+) syringaresinol.
【Specific embodiment】
In the present specification, " derivative " refers to allization that may replace position and be changed to different substituents in compound
Close object.To the type of such substituent group without limiting, such as hydroxyl, phenoxy group, thienyl, furans can be independent from each other
Base, pyridyl group, cyclohexyl, alkylol, alkane glycol (alkyl dialcohol) or the C that may replace into arbitrary phenyl1~10It is non-
Cyclic hydrocarbon group；Hydroxyl, methylol, methyl or the C that may replace into amino5~6Cyclic hydrocarbon group；Either contain saccharide residue, still
The present invention is not limited to above-mentioned substituent group.
" saccharide residue " in this specification refers to remove the base of a hydrogen atom from polysaccharide molecule, therefore can be for example
From monosaccharide or the residue of oligosaccharide.
" medicine and pharmacology permission " in this specification refers to, the energy at general drug administration amount (medicinal dosage)
Avoid stronger toxic side effect, thus should obtain the government that on animal bodies, specifically can be used on human body or
The accreditation of person's relevant authority has either obtained this accreditation or has been arranged or as general prescription medicine in pharmacy.
" salt that medicine and pharmacology allow " in this specification refers to, can obtain accreditation pharmaceutically, have parent compound
Pharmaceutical activity needed for (parent compound) and with the relevant salt of the embodiment of the present invention.Above-mentioned salt (1) can be by salt
The inorganic acids such as acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid are made or by acetic acid, propionic acid, caproic acid, 3- cyclopentanepropanoiacid acids, ethyl alcohol
Acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3- (4-
Hydroxybenzyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2- ethane disulfonic acids, 2- hydroxyethanesulfonic acids, benzene
Sulfonic acid, 4- chlorobenzenesulfonic acids, 2- naphthalene sulfonic acids, 4- toluenesulfonic acids, camphorsulfonic acid, 4- methyl bicyclics [2,2,2]-oct-2-ene -1- carboxylics
Acid, glucoheptonic acid, 3- phenylpropionic acids, trimethylace tonitric, tert-butyl acetic acid, laruyl alcohol sulfuric acid, gluconic acid, glutamic acid, hydroxyl naphthalene
Acid-addition salts made of the organic acids such as formic acid, salicylic acid, stearic acid, muconic acid (acid addition salt), (2) can also
The salt formed during containing acid proton in substituted parent compound.In addition, the compound in this specification not only includes medicine and pharmacology
The salt of permission can also include any one in all salt, hydrate, solvate that are manufactured with general method.
" (+) syringaresinol " in this specification refers to lignan compounds, can pass through chemical synthesis process
It obtains or can be extracted from least one of fruit of flaxseed, Cortex Phellodendri, cortex acanthopanacis, sesame and Radix Ginseng.
" extending the service life " in this specification, which refers to compare with natural life-span, can extend individual life span, be grown whereby
The method in service life." extend the service life " for example, above-mentioned and can also be extend various congenital or posteriority by inherent cause because
The individual life span that element determines.Specific as follows, above-mentioned " extending the service life " can adjust to influence the individual life span that inherent cause determines
Factor, such as appropriate adjust be associated with genetic expression degree, the generation degree of related protein matter, extends the service life whereby,
It includes the various factors that the various posteriorities such as appropriate adjusting ambient influence the service life, extends the service life whereby.For example, in this specification
The above-mentioned extension service life refer to, postpone the biological natural death time.
One embodiment of the invention is related to a kind of extending that (+) syringaresinol of service life composition, it spreads out for manufacturing
The purposes of salt that biology or medicine and pharmacology allow.
The other embodiment of the present invention, be related to it is a kind of by containing (+) syringaresinol, its derivative or medicine and pharmacology permit
Perhaps extension service life constituent of the salt as active ingredient.
The other embodiment of the present invention can be (+) syringaresinol in the manufacture for extend service life constituent, its derivative
The invention of the purposes of salt that object or medicine and pharmacology allow.Such use includes the complete of acology purposes or non-treatment purposes
Portion.
The other embodiment of the present invention further relates to a kind of allow (+) syringaresinol, its derivative or medicine and pharmacology
Salt is administered to individual, extends the method for the individual life span whereby.
In above-mentioned constituent related to the present invention, the total weight which can contain opposite constituent accounts for
(+) syringaresinol of the weight % of 0.001 weight %~80.When amount is in the range of this, the present invention can be preferably realized
The invention effect pursued, therefore the amount is more appropriate, and can meet the stability requirement of constituent, and cut down into
Above-mentioned present aspect containing range is also more appropriate numerical value.It is specific as follows, the amount less than 0.001 of (+) syringaresinol
During weight %, the effect for effectively extending the service life, when amount is more than 80 weight %, the safety and agent of constituent can not be obtained
The stability of type can be deteriorated.For above-mentioned viewpoint, with the relevant above-mentioned constituent of one embodiment of the invention, can contain opposite
The total weight of constituent accounts for (+) syringaresinol that the weight % of 5 weight %~60 either accounts for the weight % of 10 weight %~30.
The input amount of above-mentioned active ingredient can determine that daily input amount is for example according to the common sense of those skilled in the art
It can be g/kg/ days~5000 μ of 0.1 μ g/kg/ days, more specifically g/kg/ days~500 μ of 50 μ g/kg/ days, but not office
It is limited to above-mentioned input amount, it can be changed according to various factors such as the age of input object, health status, complication.
In relevant in preventing or treating the constituent of cardiac disorder, the above-mentioned composition with one embodiment of the invention
Object can be pharmaceutical composition.
Can will be oral, non-oral, straight with the medication of the relevant pharmaceutical composition of one embodiment of the invention
Intestines, part, percutaneous, intravenous, intramuscular, intraperitoneal, subcutaneous etc..
The dosage form orally put into can be tablet, pill, soft or hard capsules, granule, powder, granula subtilis, liquid
Body, emulsion or pellet, but it is not limited to above-mentioned shape.Such preparation can also contain diluent (example in addition to active ingredient
Such as lactose, glucose, sucrose, mannitol, sorbose, cellulose or glycine), lubricant (such as silica, talcum, tristearin
Sour either polyethylene glycol) or bonding agent (such as aluminium-magnesium silicate, starch slurry, gelatin, tragacanth, methylcellulose, carboxymethyl are fine
The plain sodium salt of dimension or polyvinylpyrrolidone).According to different situations, disintegrant, absorbent, colorant, fragrance can also be contained
The pharmacies additive such as agent or sweetener.Above-mentioned tablet can pass through common mixing, granulating or coating method system
It is standby.
The non-dosage form orally put into can be eye drops, injection, point drops, lotion, ointment, gel, frost, suspension,
Emulsion, suppository, sticking patch or spray, but it is not limited to above-mentioned form.
With the active ingredient of the relevant pharmaceutical composition of one embodiment of the invention, can according to age of input object,
Judgement of gender, weight, pathological state and its severity, administration route or the people that prescribes etc. is changed.
Those skilled in the art can determine dosage, daily dosage according to above-mentioned various factors and its professional knowledge
Such as can be g/kg/ days~100 μ of 0.1 μ g/kg/ days, more specifically g/kg/ days~50 μ of 5 μ g/kg/ days, but not office
It is limited to above-mentioned input amount.
【Specific embodiment】
In the following, the embodiment and experimental example by enumerating say the composition and effect of the present invention in more detail
It is bright.Such embodiment is provided and experimental example purpose is through understanding of the example raising shown to invention, but it is of the invention
Scope and range be not limited to above-described embodiment and experimental example.
【Experimental example 1】The effect in (+) syringaresinol extension service life is analyzed by drosophila
(1) drosophila is cultivated
By wild drosophila (Oregon-R, Canton-S, Bloomington Drosophila Stock Center
(BDSC, Bloomington, IN)) it is put into the bottle equipped with -10% yeast of 10% sucrose (SY) feed Nei and cultivates to adult.
The temperature for bringing up room maintains 25 degree, and humidity maintains 50%, and the bright state and the dim shape of 12 hours of maintenance 12 hours
State.
(2) culture medium added with sample is prepared
Prepare SY culture mediums (10% sugar, 10% dry ferment, 0.8% agar, mould resistant 0.5%, 110 μ l/ of anti-tick agent
100ml).(+) syringaresinol that concentration is respectively 100nM, 500nM is added in into the 16% SY culture mediums for be cooled to 60 DEG C
(HANCHEM CO., LTD., South Korea) sample, is cured later by cooling.The culture medium prepared by the above method is protected
There are in 4 DEG C of temperature, and use within 2 weeks.
(3) measure in service life
Into the culture medium of (+) syringaresinol sample for containing concentration being respectively 0 (comparison group), 100nM, 500nM, put
Enter be adult drosophila, every 100 of the female Drosophila of a group (cohort) of acquisition in 48 hours is put into a cage
It is interior, the culture medium more renewed two days later is placed, dead drosophila is taken out at this time and is recorded.Experiment proceeds to the institute in cage
Until having drosophila all death.With 3 cages prepared according to the various concentration of (+) syringaresinol, sum is the drosophila of 300
Establish experimental model.By Kaplan-Meier (product-limit) and log rank (generalized Savage,
Mantel-Cox) test statistics analytic approach obtains the result shown in Fig. 1.(+) syringaresinol of input can be confirmed by Fig. 1
Concentration increase when, extending the effect of life span of drosophila melanogaster can enhance.
【Experimental example 2】Extend the effect in service life by nematode analysis (+) syringaresinol
(1) prepare the carrier of nematode growth culture medium (Nematode growth medium, NGM)
3g NaCl, 17g agar-Difco, the latter same stirring to obtain mixture 955ml of 2.5g bacto peptones are added in, it will
It is put into the processing carried out in high pressure steam sterilizer (autoclave) 20 minutes.Later with time hour, stirred with electromagnetism
Device (magnetic stirrer) is mixed to be stirred mixture side while be cooled to 60 DEG C.It adds in the mixture later
1M CaCl2Ethanol solution 1ml, 1M MgSO of 1ml, 3mg/ml cholesterol4Electromagnetism is used after 1ml, 1M KPO4 buffer solutions 25ml
Blender is stirred.The NGM solution prepared by the above method is fitted into carrier, and is preserved with 4 DEG C of temperature.
(2) cultivation of Caenorhabditis elegans
Caenorhabditis elegans can obtain (University of from Caenorhabditis Genetic center
Minnesota、St.Paul、MN,USA).For the ovum (egg) selected, be added to S-basal buffers (100mM NaCl,
0.01mM cholesterol, 50mM potassium phosphates (pH6.0)) NGM carriers, with 20 DEG C of temperature, hatch 16 hours.The ovum that will be hatched
(L1 stage larvaes) is moved in NGM carriers and is cultivated to L4 larvas, containing being added in as food source in NGM carriers
Escherichia coli strain OP50。
(3) measure in service life
By L4 larvas move to containing concentration be respectively 0 (comparison group), 100nM, 250nM, 500nM (+) syringaresinol
And the S- culture mediums of (-) syringaresinol of a concentration of 500nM [are supplemented with 3mM CaCl2,3mM MgSO4,50mM EDTA,
25mM FeSO4,10mM MnCl2,10mM ZnSO4,1mM CuSO4,10mM KH2PO4 (pH6.0), the S- of E.coli OP50
Basal medium] in cultivated.The culture medium more renewed two days later is often placed, and records of the Caenorhabditis elegans to live
Number.Experimental model is established to the sum Caenorhabditis elegans of 90.The culture medium more renewed two days later is often placed, and records survival
Caenorhabditis elegans number after, pass through Kaplan-Meier (product-limit) and log rank (generalized
Savage, Mantel-Cox) test statistics analytic approach obtains result shown in Fig. 2, Fig. 3.By attached drawing it is found that (+) of input
During the concentration increase of syringaresinol, there is the effect for extending the nematode service life.It can be confirmed that (-) syringaresinol can shorten line simultaneously
The service life of worm.
【Experimental example 3】The effect in (+) syringaresinol extension service life is analyzed by mouse
By mouse when mammals measure actual life, because needing at least 2 years and needing higher cost, therefore industry
Studying the various indexs that can prove to extend service life effect.
It is for example, by the distribution of T- cell subsets, i.e., the number of CD4, CD8 memory cell is each as including humans
The aging symbol of kind mammal uses, and the index as prediction individual life span is widely used (Mechanisms of
Ageing and Development(2004),125；381-390).It is specific as follows, have been demonstrated that the number of CD4 memory cells
Increase due to the process of aging, the number of above-mentioned cell is more, regardless of individual whether ill or the disease cause, should
Individual can be more early dead (FASEB J. (1997) 11,775-783).
Because there is above-mentioned principle, the present invention can determine that the mammiferous service life prolongs by the distribution of above-mentioned T- cell subsets
Long effect.
Purchase makes it stablize a week after having the C57BL/6 mouse (central experimental animal, South Korea) at 8 months monthly ages.It will
All individuals are put into respective cage and raise, and each individual is allow to absorb sufficient feed and moisture, and temperature maintains 25
± 1 DEG C, humidity maintains 60 ± 5%, and replaces light and shade state every 12 hours.
The feed used is normal diet (Normal chow diet) (D12450B, Research Diets, New
Brunswick, NJ, USA), it records the intake of feed weekly and weight detects health status whereby.(+) syringaresinol with
The amount of daily 50mg/kg and 100mg/kg is orally put into 6 months to the mouse (10 every group) of each group.Group as a comparison
Mouse uses the mouse for only providing 6 months normal foodstuffs.
After 6 months, the blood of 400L is gone out from the vein separation of the tail portion of each mouse.1.5 times of PBS is put into the blood
Afterwards, supernatant liquid is only isolated by the centrifugation of 3000rpm.Use FITC and PE antibody (PharMingen, San
Diego, CA, USA) T- cell subsets analyses are carried out, and pass through through Miller et al.
(J.Gerontol.Biol.Med.Sci.1997；The method that 11,775-783) would know that carries out.For example following 1 institute of table of its result
Show.
【Table 1】
By above-mentioned table 1 it has been confirmed that when putting into (+) syringaresinol, the index of the bimetry in individual mice is
The number of CD4, CD8 memory cell is reduced due to the input concentration raising of (+) syringaresinol.
It is illustrated below pair with the dosage form of the relevant constituent of the embodiment of the present invention, other dosage forms can also be used.
That is, the present invention does not limit the present invention by following dosage forms, following dosage forms are only for more details present invention and list
Example.
【Dosage form example 3】Tablet
Mix (+) syringaresinol 100mg, extract of soybean 50mg, glucose 100mg, red ginseng extract 50mg, starch
After 96mg and magnesium stearate 4mg, add 30% ethyl alcohol 40mg and particle is made, later with the drying of 60 DEG C of temperature this
Grain, tablet is made into using pelleter.
【Dosage form example 4】Granule
After mixing (+) syringaresinol 100mg, extract of soybean 50mg, glucose 100mg and starch 600mg, addition
Simultaneously particle is made in 30% ethyl alcohol 100mg, is packed into after drying the particle with 60 DEG C of temperature later in packing.
【Application possibility in industry】
Constituent related to the present invention can extend a whereby using (+) syringaresinol contained as active ingredient
The service life of body.It is used as the constituent of the present invention of active ingredient by (+) syringaresinol that will contain, can extends in heredity
Aspect and people have the drosophila of perfect homology and the service life of Caenorhabditis elegans, when using it for mammal mouse,
The number of the index, i.e. CD4, CD8 memory cell of the known predictable volume lifetime of industry can be reduced.
Claims (3)
1. a kind of be used to extend service life constituent by reducing the number of CD4 memory cells or CD8 memory cells to manufacture
The purposes of salt that (+) syringaresinol or medicine and pharmacology allow.
2. purposes according to claim 1, total weight that the constituent contains opposite constituent account for 0.001 weight %~
(+) syringaresinol of 80 weight %.
3. according to purposes described in claims 1 or 2, the constituent is pharmaceutical composition.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130036394 | 2013-04-03 | ||
| KR10-2013-0036394 | 2013-04-03 | ||
| KR20140038805A KR20140120842A (en) | 2013-04-03 | 2014-04-01 | Composition for life extension containing (+)-syringaresinol |
| KR10-2014-0038805 | 2014-04-01 | ||
| PCT/KR2014/002892 WO2014163416A1 (en) | 2013-04-03 | 2014-04-03 | Composition for life extension containing (+)-syringaresinol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105246474A CN105246474A (en) | 2016-01-13 |
| CN105246474B true CN105246474B (en) | 2018-06-08 |
Family
ID=51992604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480031690.5A Active CN105246474B (en) | 2013-04-03 | 2014-04-03 | Extension service life composition containing (+) syringaresinol |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2016515614A (en) |
| KR (1) | KR20140120842A (en) |
| CN (1) | CN105246474B (en) |
| HK (1) | HK1212915A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201231049A (en) * | 2011-01-20 | 2012-08-01 | Li Tek Biolog Technology Company | Preparation process of natural components having anti-aging effect and use thereof |
-
2014
- 2014-04-01 KR KR20140038805A patent/KR20140120842A/en not_active Application Discontinuation
- 2014-04-03 JP JP2016506243A patent/JP2016515614A/en active Pending
- 2014-04-03 CN CN201480031690.5A patent/CN105246474B/en active Active
-
2016
- 2016-01-28 HK HK16100954.6A patent/HK1212915A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201231049A (en) * | 2011-01-20 | 2012-08-01 | Li Tek Biolog Technology Company | Preparation process of natural components having anti-aging effect and use thereof |
Non-Patent Citations (3)
| Title |
|---|
| Açai palm fruit (Euterpe oleracea Mart.) pulp improves survival of flies on a high fat diet;Xiaoping Sun等;《Experimental Gerontology》;20100118;第45卷;第243-251页 * |
| HPLC 测定植物中丁香脂素类物质的总含量;费嘉等;《中国中药杂志》;20060228;第31卷(第3期);第254-255页 * |
| YOUNG-WON CHIN等.Lignans and Other Constituents of the Fruits of Euterpe oleracea (Ac¸ai) with Antioxidant and Cytoprotective Activities.《JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY》.2008,第56卷(第17期),第7759-7764页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105246474A (en) | 2016-01-13 |
| HK1212915A1 (en) | 2016-06-24 |
| KR20140120842A (en) | 2014-10-14 |
| JP2016515614A (en) | 2016-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230127906A1 (en) | Formulations for extending lifespan and healthspan | |
| Shade | The science behind NMN–A stable, reliable NAD+ activator and anti-aging molecule | |
| CN102481271A (en) | Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers | |
| CN106994131B (en) | A kind of application adjusting lipid metaboli and fat compound PAQG in pharmacy | |
| JP6793380B2 (en) | Evaluation method, screening method and manufacturing method of substances that suppress the rise in blood glucose level due to sucrose intake | |
| KR101847501B1 (en) | Use of isoacteoside or pharmaceutically acceptable salt thereof | |
| US20100099918A1 (en) | Tranquilizer and Functional Food | |
| CN104017746B (en) | Lactobacillus, its composition and the application for preparing heart and hepatic disease caused by treatment erythematosus lupus | |
| US10166270B2 (en) | Composition and method for affecting cytokines and NF-κB | |
| CN105246474B (en) | Extension service life composition containing (+) syringaresinol | |
| TW201800102A (en) | Momordica charantia extract for increasing expressions of CLOCK gene, ARNTL gene, and/or PER2 gene and uses of the same | |
| TWI829090B (en) | Antidepressant, anti-aging and anti-obesity agents | |
| CN103002892A (en) | Anti-angiogenic composition containing macrolactin A and a derivative thereof as active ingredients | |
| JP2008137941A (en) | Sleep improving composition | |
| TW202200160A (en) | Composition containing sesamin or like and NR and/or NMN | |
| KR20200112898A (en) | Use of caramycin or its active ingredient | |
| EP4053129A1 (en) | Use of ginkgolide a in the treatment of autism | |
| CN103977001B (en) | A kind of antidepressant composition and application thereof | |
| CN108392585A (en) | A kind of Chinese medicine with healthcare function | |
| Bayo-Olugbami et al. | Cholecalciferol (VD3) Attenuates L-DOPA-Induced Dyskinesia in Parkinsonian Mice Via Modulation of Microglia and Oxido-Inflammatory Mechanisms | |
| KR102249706B1 (en) | Composition for life extension containing ginseng fruit extract | |
| Xie et al. | Research progress on the association between trimethylamine/trimethylamine-N-oxide and neurological disorders | |
| TW201639560A (en) | Composition for increasing or improving effectiveness of vaccine | |
| KR101844816B1 (en) | Composition For Improving Or Treating Anorexia Including Guanabenz And Method Using Thereof | |
| CN114224928A (en) | Application of elephantopus scaber extract in regulating neurotransmitter and improving anxiety behavior |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1212915 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |